FDA Lifts Advaxis Clinical Hold; Stock Surges

December 17, 2015 12:16 PM

19 0

The company announced that the FDA has lifted the clinical hold on all of the company's Investigational New Drug (IND) applications for its three product candidates: axalimogene filolisbac, ADXS-PSA and ADXS-HER2.

In October, the agency put on axalimogene filolisbac after a death of patient. The company clarified that the drug was not responsible for the death, which occurred due to progression of cervical cancer. In all, nine clinical trials were halted and all will resume immediately. The drug is now being ...

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page